<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01098071</url>
  </required_header>
  <id_info>
    <org_study_id>P04367 - Lebanon</org_study_id>
    <nct_id>NCT01098071</nct_id>
  </id_info>
  <brief_title>Nasonex (Mometasone Furoate Nasal Spray) in Adenoids Hypertrophy in Children (P04367)</brief_title>
  <acronym>NAHCh</acronym>
  <official_title>Open Label Pilot Trial, Evaluating the Role of Nasonex in the Management of Nasal Obstruction Secondary to Adenoids Hypertrophy in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To document the short term &amp; long term effect of treatment with Nasonex (mometasone furoate
      nasal spray) in moderate to severe adenoids hypertrophy (which cause &gt; 50% obstruction of the
      posterior choanae).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2008</start_date>
  <completion_date type="Actual">September 1, 2009</completion_date>
  <primary_completion_date type="Actual">September 1, 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of Nasal Obstruction Symptoms at Baseline and Week 12 as Measured by the Total Clinical Score</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Clinical score (based on a 5 point grading system) was assessed for each of 5 nasal obstruction symptoms (oral/mouth breathing, snoring, restless sleep, frequent waking-ups during the night, and obstructive breathing during sleep). Each nasal obstruction symptom was estimated by the parent/guardian of the participant and scored on a scale of 0 (best) to 1 (worst). Total clinical score is a score on a scale (0 = no symptoms [best score] and 5 = worst symptoms [worst score]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Degree of Posterior Choana Obstruction at Baseline and Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The degree of obstruction of the posterior choana was assessed by endoscopy. Endoscopy grading consisted of Grade I (minimum), Grade II and Grade III (maximum). Grade I was defined as &lt;50% obstruction, Grade II was defined as 50-75% obstruction, and Grade III was defined as &gt;75% obstruction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Referred to Surgery (Adenoidectomy) Within 12 Weeks of Start of Therapy</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of Rhinorrhea at Baseline and Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Rhinorrhea is a symptom of allergic rhinitis. Rhinorrhea was assessed using a 3-point scale (0 = no symptoms [best score] and 3 = symptom interferes with daily life activity [worst score]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Nasal Congestion at Baseline and Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Nasal congestion is a symptom of allergic rhinitis. Nasal congestion was assessed using a 3-point scale (0 = no symptoms [best score] and 3 = symptom interferes with daily life activity [worst score]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Nasal Itching at Baseline and Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Nasal itching is a symptom of allergic rhinitis. Nasal itching was assessed using a 3-point scale (0 = no symptoms [best score] and 3 = symptom interferes with daily life activity [worst score]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Sneezing at Baseline and Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Sneezing is a symptom of allergic rhinitis. Sneezing was assessed using a 3-point scale (0 = no symptoms [best score] and 3 = symptom interferes with daily life activity [worst score]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Eye Symptoms at Baseline and Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Eye symptoms are a symptom of allergic rhinitis. Eye symptoms were assessed using a 3-point scale (0 = no symptoms [best score] and 3 = symptom interferes with daily life activity [worst score]).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Adenoids</condition>
  <arm_group>
    <arm_group_label>mometasone furoate nasal spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mometasone furoate nasal spray</intervention_name>
    <description>One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months</description>
    <arm_group_label>mometasone furoate nasal spray</arm_group_label>
    <other_name>SCH 32088</other_name>
    <other_name>Nasonex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  2-11 years of age, nasal obstruction for 3 months, adenoids hypertrophy &gt; 50% of
             posterior choanae.

        Exclusion Criteria:

          -  adenoids hypertrophy &lt; 50% of posterior choanae

        recurrent epistaxis or immunodeficiency, severe septal deviation, kissing tonsils, choanal
        atresia, large masses, known allergy to nasonex (mometasone furoate nasal spray), chronic
        otitis media, cystic fibrosis, acute infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <results_reference>
    <citation>Bitar MA, Mahfoud L, Nassar J, Dana R. Exploring the characteristics of children with obstructive adenoid responding to mometasone fuorate monohydrate: preliminary results. Eur Arch Otorhinolaryngol. 2013 Mar;270(3):931-7. doi: 10.1007/s00405-012-2155-8. Epub 2012 Aug 22.</citation>
    <PMID>23010795</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2010</study_first_submitted>
  <study_first_submitted_qc>April 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2010</study_first_posted>
  <results_first_submitted>June 13, 2011</results_first_submitted>
  <results_first_submitted_qc>October 20, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 29, 2011</results_first_posted>
  <last_update_submitted>September 15, 2017</last_update_submitted>
  <last_update_submitted_qc>September 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mometasone Furoate Nasal Spray</title>
          <description>One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Surgery (adenoidectomy)</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mometasone Furoate Nasal Spray</title>
          <description>One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.84" lower_limit="0.5" upper_limit="9.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Lebanon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Severity of Nasal Obstruction Symptoms at Baseline and Week 12 as Measured by the Total Clinical Score</title>
        <description>Clinical score (based on a 5 point grading system) was assessed for each of 5 nasal obstruction symptoms (oral/mouth breathing, snoring, restless sleep, frequent waking-ups during the night, and obstructive breathing during sleep). Each nasal obstruction symptom was estimated by the parent/guardian of the participant and scored on a scale of 0 (best) to 1 (worst). Total clinical score is a score on a scale (0 = no symptoms [best score] and 5 = worst symptoms [worst score]).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate Nasal Spray</title>
            <description>One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Nasal Obstruction Symptoms at Baseline and Week 12 as Measured by the Total Clinical Score</title>
          <description>Clinical score (based on a 5 point grading system) was assessed for each of 5 nasal obstruction symptoms (oral/mouth breathing, snoring, restless sleep, frequent waking-ups during the night, and obstructive breathing during sleep). Each nasal obstruction symptom was estimated by the parent/guardian of the participant and scored on a scale of 0 (best) to 1 (worst). Total clinical score is a score on a scale (0 = no symptoms [best score] and 5 = worst symptoms [worst score]).</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.89" lower_limit="2" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Degree of Posterior Choana Obstruction at Baseline and Week 12</title>
        <description>The degree of obstruction of the posterior choana was assessed by endoscopy. Endoscopy grading consisted of Grade I (minimum), Grade II and Grade III (maximum). Grade I was defined as &lt;50% obstruction, Grade II was defined as 50-75% obstruction, and Grade III was defined as &gt;75% obstruction.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Only participants that completed the study are included.</population>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate Nasal Spray</title>
            <description>One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Degree of Posterior Choana Obstruction at Baseline and Week 12</title>
          <description>The degree of obstruction of the posterior choana was assessed by endoscopy. Endoscopy grading consisted of Grade I (minimum), Grade II and Grade III (maximum). Grade I was defined as &lt;50% obstruction, Grade II was defined as 50-75% obstruction, and Grade III was defined as &gt;75% obstruction.</description>
          <population>Only participants that completed the study are included.</population>
          <units>Percent obstruction</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="70" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="40" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Referred to Surgery (Adenoidectomy) Within 12 Weeks of Start of Therapy</title>
        <time_frame>Baseline to 12 weeks</time_frame>
        <population>Evaluable population (per protocol population, ie, those participants without protocol violation of inclusion or exclusion criteria)</population>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate Nasal Spray</title>
            <description>One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Referred to Surgery (Adenoidectomy) Within 12 Weeks of Start of Therapy</title>
          <population>Evaluable population (per protocol population, ie, those participants without protocol violation of inclusion or exclusion criteria)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Rhinorrhea at Baseline and Week 12</title>
        <description>Rhinorrhea is a symptom of allergic rhinitis. Rhinorrhea was assessed using a 3-point scale (0 = no symptoms [best score] and 3 = symptom interferes with daily life activity [worst score]).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Participants suspected to have allergic rhinitis</population>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate Nasal Spray</title>
            <description>One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Rhinorrhea at Baseline and Week 12</title>
          <description>Rhinorrhea is a symptom of allergic rhinitis. Rhinorrhea was assessed using a 3-point scale (0 = no symptoms [best score] and 3 = symptom interferes with daily life activity [worst score]).</description>
          <population>Participants suspected to have allergic rhinitis</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Nasal Congestion at Baseline and Week 12</title>
        <description>Nasal congestion is a symptom of allergic rhinitis. Nasal congestion was assessed using a 3-point scale (0 = no symptoms [best score] and 3 = symptom interferes with daily life activity [worst score]).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Participants suspected to have allergic rhinitis</population>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate Nasal Spray</title>
            <description>One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Nasal Congestion at Baseline and Week 12</title>
          <description>Nasal congestion is a symptom of allergic rhinitis. Nasal congestion was assessed using a 3-point scale (0 = no symptoms [best score] and 3 = symptom interferes with daily life activity [worst score]).</description>
          <population>Participants suspected to have allergic rhinitis</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Nasal Itching at Baseline and Week 12</title>
        <description>Nasal itching is a symptom of allergic rhinitis. Nasal itching was assessed using a 3-point scale (0 = no symptoms [best score] and 3 = symptom interferes with daily life activity [worst score]).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Participants suspected to have allergic rhinitis</population>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate Nasal Spray</title>
            <description>One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Nasal Itching at Baseline and Week 12</title>
          <description>Nasal itching is a symptom of allergic rhinitis. Nasal itching was assessed using a 3-point scale (0 = no symptoms [best score] and 3 = symptom interferes with daily life activity [worst score]).</description>
          <population>Participants suspected to have allergic rhinitis</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Sneezing at Baseline and Week 12</title>
        <description>Sneezing is a symptom of allergic rhinitis. Sneezing was assessed using a 3-point scale (0 = no symptoms [best score] and 3 = symptom interferes with daily life activity [worst score]).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Participants suspected to have allergic rhinitis</population>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate Nasal Spray</title>
            <description>One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Sneezing at Baseline and Week 12</title>
          <description>Sneezing is a symptom of allergic rhinitis. Sneezing was assessed using a 3-point scale (0 = no symptoms [best score] and 3 = symptom interferes with daily life activity [worst score]).</description>
          <population>Participants suspected to have allergic rhinitis</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Eye Symptoms at Baseline and Week 12</title>
        <description>Eye symptoms are a symptom of allergic rhinitis. Eye symptoms were assessed using a 3-point scale (0 = no symptoms [best score] and 3 = symptom interferes with daily life activity [worst score]).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Participants suspected to have allergic rhinitis</population>
        <group_list>
          <group group_id="O1">
            <title>Mometasone Furoate Nasal Spray</title>
            <description>One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Eye Symptoms at Baseline and Week 12</title>
          <description>Eye symptoms are a symptom of allergic rhinitis. Eye symptoms were assessed using a 3-point scale (0 = no symptoms [best score] and 3 = symptom interferes with daily life activity [worst score]).</description>
          <population>Participants suspected to have allergic rhinitis</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Score at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>In this study, symptoms of allergic rhinitis (rhinorrhea, nasal congestion, nasal itching, sneezing, and eye symptoms) were not reported as adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Mometasone Furoate Nasal Spray</title>
          <description>One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The principal investigator and his co-workers agree not to publish or publicly present any results of the study without the prior written consent and approval of the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck, Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

